Li-Fraumeni-associated osteosarcomas: The French experience.
Li–Fraumeni syndrome
TP53 variants
chondroblastic osteosarcoma
jaw osteosarcoma
osteosarcoma
osteosarcomatosis
periosteal osteosarcoma
predisposition
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
10 Oct 2024
10 Oct 2024
Historique:
revised:
28
08
2024
received:
11
06
2024
accepted:
18
09
2024
medline:
13
10
2024
pubmed:
13
10
2024
entrez:
10
10
2024
Statut:
aheadofprint
Résumé
Describe clinical characteristics and outcome of Li-Fraumeni syndrome (LFS)-associated osteosarcomas. TP53 germline pathogenic/likely pathogenic variant carriers diagnosed with osteosarcoma in France between 1980 and 2019 were identified via the French Li-Fraumeni database at Rouen University Hospital. Sixty-five osteosarcomas in 52 patients with available clinical and histological data were included. The main clinical characteristics were compared with data from National Cancer Institute's SEER (Surveillance, Epidemiology, and End Results) for patients of the same age group. Median age at first osteosarcoma diagnosis was 13.7 years (range: 5.9-36.7). Compared to unselected osteosarcomas, LFS-associated osteosarcomas occurred more frequently in patients less than 10 years of age (23% vs. 9%), and when compared with osteosarcomas in patients less than 25 years were characterized by an excess of axial (16% vs. 10%) and jaw sites (15% vs. 3%) and histology with predominant chondroblastic component and periosteal subtypes (17% vs. 1%). Metastases incidence (25%) was as expected in osteosarcomas. After the first osteosarcoma treatment, the rate of good histologic response (62%) and the 5-year progression-free survival (55%, 95% confidence interval [CI]: 42.6-71.1) were as expected in unselected series of osteosarcomas, whereas the 5-year event-free survival was 36.5% [95% CI: 25.3-52.7] due to the high incidence of second malignancies reaching a 10-year cumulative risk of 43.4% [95% CI: 28.5-57.5]. In osteosarcoma, young age at diagnosis, axial and jaw sites, histology with periosteal or chondroblastic subtype, and synchronous multifocal tumors should prompt suspicion of a germline TP53 mutation. Standard treatments are effective, but multiple malignancies impair prognosis. Early recognition of these patients is crucial for tailored therapy and follow-up.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e31362Informations de copyright
© 2024 The Author(s). Pediatric Blood & Cancer published by Wiley Periodicals LLC.
Références
Soft Tissue and Bone Tumours. WHO Classification of Tumours. 5th ed. WHO Classification of Tumours Editorial Board; 2020.
Mirabello L, Zhu B, Koster R, et al. Frequency of pathogenic germline variants in cancer‐susceptibility genes in patients with osteosarcoma. JAMA Oncol. 2020;6:724‐734.
Li FP, Fraumeni JF. Soft‐tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome? Ann Intern Med. 1969;71:747‐752.
Ognjanovic S, Olivier M, Bergemann TL, Hainaut P. Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. Cancer. 2012;118:1387‐1396.
Mitchell G, Ballinger ML, Wong S, et al. International Sarcoma Kindred Study. High frequency of germline TP53 mutations in a prospective adult‐onset sarcoma cohort. PLoS One. 2013;8:e69026.
Mirabello L, Yeager M, Mai PL, et al. Germline TP53 variants and susceptibility to osteosarcoma. J Natl Cancer Inst. 2015;107:djv101.
Bougeard G, Renaux‐Petel M, Flaman JM, et al. Revisiting Li–Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol. 2015;33:2345‐2352.
Mai PL, Best AF, Peters JA, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li–Fraumeni syndrome cohort. Cancer. 2016;122:3673‐3681.
Nutting C, Camplejohn RS, Gilchrist R, et al. A patient with 17 primary tumours and a germ line mutation in TP53: tumour induction by adjuvant therapy? Clin Oncol (R Coll Radiol). 2000;12:300‐304.
Thariat J, Chevalier F, Orbach D, et al. Avoidance or adaptation of radiotherapy in patients with cancer with Li–Fraumeni and heritable TP53‐related cancer syndromes. Lancet Oncol. 2021;22:e562‐e574.
Salmon A, Amikam D, Sodha N, et al. Rapid development of post‐radiotherapy sarcoma and breast cancer in a patient with a novel germline ‘de‐novo’ TP53 mutation. Clin Oncol (R Coll Radiol). 2007;19:490‐493.
Kasper E, Angot E, Colasse E, et al. Contribution of genotoxic anticancer treatments to the development of multiple primary tumours in the context of germline TP53 mutations. Eur J Cancer. 2018;101:254‐262.
Zerdoumi Y, Kasper E, Soubigou F, et al. A new genotoxicity assay based on p53 target gene induction. Mutat Res Toxicol Environ Mutagen. 2015;789‐790:28‐35.
Zerdoumi Y, Lanos R, Raad S, et al. Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage. Hum Mol Genet. 2017;26:2591‐2602.
Frebourg T, Bajalica Lagercrantz S, Oliveira C, Magenheim R, Evans DG, European Reference Network GENTURIS. Guidelines for the Li–Fraumeni and heritable TP53‐related cancer syndromes. Eur J Hum Genet. 2020;28:1379‐1386.
Kratz CP, Achatz MI, Brugières L, et al. Cancer screening recommendations for individuals with Li–Fraumeni syndrome. Clin Cancer Res. 2017;23:e38‐e45.
Chompret A, Abel A, Stoppa‐Lyonnet D, et al. Sensitivity and predictive value of criteria for p53germline mutation screening. J Med Genet. 2001;38:43‐47.
Tinat J, Bougeard G, Baert‐Desurmont S, et al. 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol. 2009;27:e108‐e109.
Renaux‐Petel M, Charbonnier F, Théry JC, et al. Contribution of de novo and mosaic TP53 mutations to Li–Fraumeni syndrome. J Med Genet. 2018;55:173‐180.
Diessner BJ, Pankratz N, Hooten AJ, et al. Nearly half of TP53 germline variants predicted to be pathogenic in patients with osteosarcoma are de novo: a report from the Children's Oncology Group. JCO Precis Oncol. 2020;4:PO.20.00087.
Cole S, Gianferante DM, Zhu B, Mirabello L. Osteosarcoma: a Surveillance, Epidemiology, and End Results program‐based analysis from 1975 to 2017. Cancer. 2022;128:2107‐2118.
de Andrade KC, Lee EE, Tookmanian EM, et al. The TP53 database: transition from the International Agency for Research on Cancer to the US National Cancer Institute. Cell Death Differ. 2022;29:1071‐1073.
Gaspar N, Occean BV, Pacquement H, et al. Results of methotrexate‐etoposide‐ifosfamide based regimen (M‐EI) in osteosarcoma patients included in the French OS2006/sarcome‐09 study. Eur J Cancer. 2018;88:57‐66.
McIntyre JF, Smith‐Sorensen B, Friend SH, et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol. 1994;12:925‐930.
Toguchida J, Yamaguchi T, Dayton SH, et al. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med. 1992;326:1301‐1308.
Shaul E, Roth M, Lo Y, et al. Pediatric oncologist willingness to offer germline TP53 testing in osteosarcoma. Cancer. 2018;124:1242‐1250.
Luo M, Wong D, Zelley K, et al. Identification of TP53 germline variants in pediatric patients undergoing tumor testing: strategy and prevalence. J Natl Cancer Inst. 2024;116:1356‐1365.
Droin‐Mollard M, de Montgolfier S, Gimenez‐Roqueplo AP, et al. Psychological and ethical issues raised by genomic in paediatric care pathway, a qualitative analysis with parents and childhood cancer patients. Eur J Hum Genet. 2024. doi:10.1038/s41431‐024‐01653‐4
Agir H, MacKinnon C, Tan ST. Li–Fraumeni syndrome: a case with 4 separate primary sarcomas and 5 sequential free flaps in the maxillofacial region. J Oral Maxillofac Surg. 2008;66:1714‐1719.
Khayat CM, Johnston DL. Rhabdomyosarcoma, osteosarcoma, and adrenocortical carcinoma in a child with a germline p53 mutation. Pediatr Blood Cancer. 2004;43:683‐686.
Ginat D, Schulte J, Gooi Z, Cipriani N. High‐grade conventional osteosarcoma of the mandible associated with P53 germline mutation. J Craniofac Surg. 2018;29:738‐740.
Meazza C, Luksch R, Daolio P, et al. Axial skeletal osteosarcoma: a 25‐year monoinstitutional experience in children and adolescents. Med Oncol. 2014;31:875.
Thariat J, Schouman T, Brouchet A, et al. Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF‐GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE. Ann Oncol. 2013;24:824‐831.
Garcia Garcia A, Barros F, Bouzas ML, Penaranda JM. Li–Fraumeni syndrome and osteosarcoma of the maxilla. J Oral Maxillofac Surg. 1998;56:1106‐1109.
Hauben EI, Arends J, Vandenbroucke JP, van Asperen CJ, Van Marck E, Hogendoorn PCW. Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma. Eur J Hum Genet. 2003;11:611‐618.
Maheshwari AV, Jelinek JS, Seibel NL, Meloni‐Ehrig AM, Kumar D, Henshaw RM. Bilateral synchronous tibial periosteal osteosarcoma with familial incidence. Skeletal Radiol. 2012;41:1005‐1009.
Hopper KD, Moser RP Jr, Haseman DB, Sweet DE, Madewell JE, Kransdorf MJ. Osteosarcomatosis. Radiology. 1990;175:233‐239.
Smeland S, Bielack SS, Whelan JS, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS‐1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019;109:36‐50.
Piperno‐Neumann S, Le Deley M‐C, Rédini F, et al. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncol. 2016;17:1070‐1080.
Wunder JS, Gokgoz N, Parkes R, et al. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol. 2005;23:1483‐1490.
Hesla AC, Discacciati A, Tsagkozis P, Smedby KE. Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow‐up and in the latest treatment era, a nationwide population‐based study. Br J Cancer. 2020;122:1242‐1249.
Fidler MM, Frobisher C, Guha J, et al. Long‐term adverse outcomes in survivors of childhood bone sarcoma: the British Childhood Cancer Survivor Study. Br J Cancer. 2015;112:1857‐1865.
Fidler MM, Reulen RC, Winter DL, et al. Risk of subsequent bone cancers among 69 460 five‐year survivors of childhood and adolescent cancer in Europe. J Natl Cancer Inst. 2018;110:183‐194.
Freedman IG, Dowd HN, Dhodapkar MM, Halperin SJ, Grauer JN. Second primary malignancies of the bones and joints: more common than expected in osteosarcoma patients. J Am Acad Orthop Surg Glob Res Rev. 2023;7:e22.00275.
Lengner CJ, Steinman HA, Gagnon J, et al. Osteoblast differentiation and skeletal development are regulated by Mdm2‐p53 signaling. J Cell Biol. 2006;172:909‐921.
Ferri A, Bianchi B, Ferrari S. Mandibular osteosarcoma: diagnosis and treatment. Curr Opin Otolaryngol Head Neck Surg. 2022;30:154‐160.
Villani A, Shore A, Wasserman JD, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li–Fraumeni syndrome: 11 year follow‐up of a prospective observational study. Lancet Oncol. 2016;17:1295‐1305.
Ballinger ML, Best A, Mai PL, et al. Baseline surveillance in Li–Fraumeni syndrome using whole‐body magnetic resonance imaging: a meta‐analysis. JAMA Oncol. 2017;3:1634‐1639.